CYP21 Genotype, Adult Height, and Pubertal Development in 55 Patients Treated for 21-Hydroxylase Deficiency
The DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
Abstract
In a retrospective study we evaluated long-term growth, pubertal developmental patterns to final height (FH), and medication in 55 patients (35 females) affected by 21-hydroxylase deficiency. The patients were classified into 3 groups according to predicted mutation severity: group A (11 women and 9 men), homozygous or compound heterozygous for null or In2 splice mutations [residual enzymatic activity (RA), <1%]; group B (11 women and 4 men), homozygous for I172N or R341P or R426H mutations (RA, approximately 2-3%) or compound heterozygous with any of the group A or B mutations; and group C (13 women and 7 men), homozygous for P30L or V281L or P453S mutations (RA, >30%) or compound heterozygous with any of the group A, B, or C mutations. Three patients showed unclassifiable genotypes. FH was similar in the female groups, whereas male patients in group B were shorter than males in groups A and C. Fifty-five percent of patients in group A, 33% in group B, and 40% in group C reached an FH within 0.5 SD of target height. Four of the 7 patients diagnosed via neonatal screening achieved an FH equal to or above the target height. In the entire group, early diagnosis (<1 yr) improved height outcome. Early diagnosed CAH patients who received lower cortisol equivalent doses during the first year of life reached a better FH. Our results underline the importance of mineralocorticoid therapy, as CAH subjects in groups A and B who did not receive this treatment showed reduced FH. Early diagnosis, the use of more physiological cortisol equivalent dosages during the first year of life, and the extension of mineralocorticoid therapy to all classical patients are shown to improve the auxological outcome. Genotypic analysis helped to interpret the height results of our cases and prospectively may represent a useful tool for improving the therapeutic choice and the height outcome.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A similar correlation of severity with genotype is seen when evaluating genital appearance in adult women (224).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [224]
In the citing paper
“There are limited data directly correlating psychosexual functioning with genotype (224,225),”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [224]
In the citing paper
“When doses exceed 20 mg/m 2 per day in infants or 15 to 17 mg/m 2 per day in adolescents, there is a decrease in height standard deviation score (SDS), leading to a decreased adult height SDS (196)(197)(198)(199).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [196]
Citations
Cites
Variations in pattern of pubertal changes in girls
Marshall, W. A., & Tanner, J. M. (1969) · Archives of Disease in Childhood · doi:10.1136/adc.44.235.291 · Cited by 5,963
Variations in the pattern of pubertal changes in boys
Marshall, W. A., & Tanner, J. M. (1970) · Archives of Disease in Childhood · doi:10.1136/adc.45.239.13 · Cited by 5,147 · cited 3×
“Pubertal maturation was assessed by the Marshall and Tanner method (14, 15), whereas body mass index (BMI; kilograms per square meter) sd scores were calculated according to the reference standards of Roland-Cachera et al.”
BackgroundMethodTanner, J. M., Whitehouse, R. H., & Takaishi, M. (1966) · Archives of Disease in Childhood · doi:10.1136/adc.41.220.613 · Cited by 2,553
Tanner, J. M., Whitehouse, R. H., & Takaishi, M. (1966) · Archives of Disease in Childhood · doi:10.1136/adc.41.219.454 · Cited by 1,345
Bayley, N., & Pinneau, S. R. (1952) · The Journal of Pediatrics · doi:10.1016/s0022-3476(52)80205-7 · Cited by 1,196
Body Mass Index variations: centiles from birth to 87 years.
Rolland‐Cachera, M., Cole, T. J., Sempe, M., Tichet, J., Rossignol, C., & Charraud, A.-M. (1991) · PubMed · Cited by 1,127
Speiser, P. W., Dupont, J., Zhu, D., Serrat, J., Buegeleisen, M., Tusie-Luna, M. T., Lesser, M., New, M. I., & White, P. C. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115897 · Cited by 572 · cited 2×
“Group A consisted of patients homozygous or compound heterozygous for null (deletion, large/small conversion, Del8bp, CluE6) or In2 splice (In2) mutations [residual enzymatic activity (RA), 1%; Table 1, cases 1–20) (7, 8).”
BackgroundItalian cross-sectional growth charts for height, weight and BMI (6–20 y)
Cacciari, E., Milani, S., Balsamo, A., Dammacco, F., De Luca, F., Chiarelli, F., Pasquino, A., Tonini, G., & Vanelli, M. (2002) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1601314 · Cited by 387
Self-citationWedell, A. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.5.1145 · Cited by 370
Long Term Outcome in Adult Males with Classic Congenital Adrenal Hyperplasia1
Cabrera, M. S., Vogiatzi, M. G., & New, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7668 · Cited by 204
Research works printed but not linked: 4
- Aicardi, 1986, Affidabilitá dei più comuni metodi di previsione della statura adulta in un campione di adolescenti italiani., Acta Med Auxol, 18, 55
- Ehrlich, 1989, Electrolyte metabolism, 1594
- Styne, 1977, Growth patterns in congenital adrenal hyperplasia: correlation of glucocorticoid therapy with stature, In: Lee PA, Plotnick LP, Kowarski AA, Migeon CJ, eds. Congenital adrenal hyperplasia. Baltimore: University Park Press;, 247
- New, 1989, Final height in classical and non classical 21-hydroxylase deficiency adrenal hyperplasis, In: Bierich JR, Cacciari E, Raiti S, eds. Growth abnormalities. New York: Raven Press;, 51
Cited by
Items 101–112 of 112
Debates and controversies in genetic steroid disorders
Speiser, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00014-9
Growth hormone treatment in children with congenital adrenal hyperplasia
Lin‐Su, K., Lekarev, O., & New, M. I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00023-x
21-Hydroxylase deficiency: Clinical and biochemical aspects
Nordenström, A., & Lajić, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00171-0
The assessment of outcomes in rare endocrine conditions
Ali, S. (2023) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.83681
Kıraç, D. (2009) · Dspace Repository (Marmara Üniversitesi)
Ribas, D. C. (2006) · DSpace (Federal University of Santa Catarina)
Les hyperplasies congénitales des surrénales
Alsalama, T. (2016) · Dépôt Institutionnel de lUniversité de Tlemcen
The evolution of new approaches to the treatment of congenital adrenal hyperplasia
Merke, D. P., & Auchus, R. J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag033
Management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: an update
Bobrowicz, M., Roszkowska, Z., Domański, J., Ginalska-Malinowska, M., Rak, B., Gastoł, P., Betlejewska, J., Gładka, A., Hubska, J., & Ambroziak, U. (2026) · Endokrynologia Polska · doi:10.5603/ep.110211
Gawlik, Z., Gawlik, J., Tyrawa, K., Starzyk, J., & Januś, D. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-07454-9
Suzuki, S., Kashimada, K., Mukai, T., Katsumata, N., Ishii, T., Tajima, T., Shibata, H., & Hasegawa, T. (2026) · Endocrine Journal · doi:10.1507/endocrj.ej26-0277
Assessment of Physical Growth in Children with Congenital Adrenal Hyperplasia (CAH)
Czapla, Z., Niedziela, M., & Cieślik, J. J. (2008) · Repozytorium Uniwersytetu im. Adama Mickiewicza (Adam Mickiewicz University in Poznań)
Metadata
- Authors
- Balsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E.
- Affiliations
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Corresponding author
- Cacciari, Emanuele
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-12-01
- Volume
- 88
- Issue
- 12
- Pages
- 5680-5688
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2074732687
- Cited by
- 102
- References
- 37
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 10 · 2012: 2
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- 21-hydroxylase deficiency, congenital adrenal hyperplasia, adult height, pubertal development, mineralocorticoid therapy, early diagnosis, newborn screening, residual enzyme activity, compound heterozygosity, genotype-phenotype correlation, growth outcomes
- MeSH terms
- Adrenal Hyperplasia, Congenital, Aging, Body Height, Child, Child, Preschool, Female, Fertility, Genotype, Humans, Infant, Infant, Newborn, Male, Mineralocorticoids, Prognosis, Puberty, Retrospective Studies, Steroid 21-Hydroxylase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.